{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:06Z","timestamp":1790803686937,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T20:33:24Z","timestamp":1764448404000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Differences in pulmonary exacerbation risks among CF subpopulations"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"D.R.","family":"VanDevanter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"O'Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"M.W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Mayer","family":"Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcf.2025.11.010_bib0001","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2005.10.019","article-title":"Cystic fibrosis pulmonary exacerbations","volume":"148","author":"Ferkol","year":"2006","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.010_bib0002","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.010_bib0003","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/MCP.0000000000000730","article-title":"Treatment of pulmonary exacerbations in cystic fibrosis","volume":"26","author":"Ng","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.010_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/cli.11.174","article-title":"Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease","volume":"2","author":"VanDevanter","year":"2012","journal-title":"Clin Invest"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.010_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2020.07.008","article-title":"Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.010_bib0006","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jcf.2015.10.006","article-title":"IV-treated pulmonary exacerbations in the prior year: an important independent risk factor for future pulmonary exacerbation in cystic fibrosis","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.11.010_bib0007","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry: design and Methods of a National Observational Disease Registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.jcf.2025.11.010_bib0008","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.010_bib0009","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.11.010_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v070.i08","article-title":"Flexsurv: a platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jcf.2025.11.010_bib0011","series-title":"R: a language and environment for statistical computing","year":"2024"},{"issue":"19","key":"10.1016\/j.jcf.2025.11.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1908639","article-title":"VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.010_bib0013","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcf.2021.08.007","article-title":"EMPIRE-CF study group. Empire-CF study: a phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis","volume":"20","author":"Elborn","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2025.11.010_bib0014","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.11.010_bib0015","unstructured":"2024 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103532s5194lbl.pdf."},{"issue":"4","key":"10.1016\/j.jcf.2025.11.010_bib0016","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.010_bib0017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Elborn","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2025.11.010_bib0018","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.11.010_bib0019","unstructured":"US Food and Drug Administration. Anti-Infective Drugs Advisory Committee Meeting. Briefing Document for Aztreonam for Inhalation Solution (NDA 50-814) for Improvement of Respiratory Symptoms in Cystic Fibrosis Patients. 2009."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932502507X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932502507X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:36:47Z","timestamp":1781782607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932502507X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S156919932502507X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in pulmonary exacerbation risks among CF subpopulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}